Jefferies Financial Group Inc. Has $4.23 Million Stake in Medpace Holdings, Inc. $MEDP

Jefferies Financial Group Inc. lowered its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 67.4% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,232 shares of the company’s stock after selling 17,021 shares during the period. Jefferies Financial Group Inc.’s holdings in Medpace were worth $4,233,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Clarkston Capital Partners LLC acquired a new position in shares of Medpace in the second quarter valued at approximately $40,569,000. Cibc World Market Inc. acquired a new stake in Medpace during the 3rd quarter worth approximately $5,033,000. Brighton Jones LLC boosted its position in Medpace by 160.4% during the 3rd quarter. Brighton Jones LLC now owns 4,060 shares of the company’s stock worth $2,087,000 after buying an additional 2,501 shares during the period. Wealth Enhancement Advisory Services LLC grew its holdings in Medpace by 150.0% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 15,193 shares of the company’s stock worth $8,080,000 after acquiring an additional 9,117 shares during the last quarter. Finally, Baillie Gifford & Co. grew its holdings in Medpace by 12.0% during the 3rd quarter. Baillie Gifford & Co. now owns 584,796 shares of the company’s stock worth $300,679,000 after acquiring an additional 62,503 shares during the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

NASDAQ:MEDP opened at $478.54 on Tuesday. Medpace Holdings, Inc. has a fifty-two week low of $250.05 and a fifty-two week high of $628.92. The company has a 50 day simple moving average of $532.11 and a two-hundred day simple moving average of $539.65. The company has a market capitalization of $13.58 billion, a PE ratio of 31.28, a P/E/G ratio of 2.26 and a beta of 1.44.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $4.18 by $0.49. Medpace had a net margin of 17.83% and a return on equity of 118.82%. The firm had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. During the same quarter in the previous year, the company earned $3.67 EPS. The company’s revenue for the quarter was up 32.0% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Research analysts predict that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on MEDP. Mizuho set a $582.00 price target on shares of Medpace in a research note on Wednesday, February 11th. BMO Capital Markets reissued a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and reduced their price objective for the stock from $462.00 to $419.00 in a research note on Wednesday, February 18th. Zacks Research downgraded Medpace from a “strong-buy” rating to a “hold” rating in a report on Monday, January 12th. Finally, Royal Bank Of Canada started coverage on Medpace in a research report on Tuesday, March 3rd. They set an “outperform” rating and a $522.00 target price for the company. Five analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Medpace presently has a consensus rating of “Hold” and a consensus price target of $486.67.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.